Edition:
United States

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

1.12USD
4:00pm EDT
Change (% chg)

$-0.06 (-5.08%)
Prev Close
$1.18
Open
$1.17
Day's High
$1.20
Day's Low
$1.12
Volume
21,770
Avg. Vol
60,928
52-wk High
$3.38
52-wk Low
$0.74

BIOC.OQ

Chart for BIOC.OQ

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $35.70
Shares Outstanding(Mil.): 30.25
Dividend: --
Yield (%): --

Financials

  BIOC.OQ Industry Sector
P/E (TTM): -- 29.96 32.62
EPS (TTM): -1.64 -- --
ROI: -237.47 13.85 14.94
ROE: -361.71 16.65 16.18

BRIEF-Biocept Inc files for disposition of up to 2.9 million shares of common stock

* Biocept Inc files for disposition of up to 2.9 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2fShoIH) Further company coverage:

Aug 18 2017

BRIEF-Biocept, UT Southwestern Medical Center announce clinical study to profile, monitor non-small cell lung cancer patients

* Biocept and UT Southwestern medical center announce clinical study to profile and monitor non-small cell lung cancer patients with ALK rearrangements Source text for Eikon: Further company coverage:

Aug 17 2017

BRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR

* Biocept enters into exclusive distribution agreement with Global Laboratory Product Supplier VWR

Aug 14 2017

BRIEF-Biocept Q2 loss per share $0.21

* Says ‍revenues for Q2 of 2017 increased 93% to $1.3 million​

Aug 10 2017

BRIEF-Biocept announces private placement of $2.2 mln of common stock

* Biocept announces private placement of $2.2 million of common stock with Ally Bridge LB Healthcare Master Fund

Aug 10 2017

BRIEF-Biocept executes preferred provider agreement with Scripps Health Plan

* Biocept executes preferred provider agreement with Scripps Health Plan expanding patient coverage for its liquid biopsy platform Source text for Eikon: Further company coverage:

Aug 07 2017

BRIEF-Biocept launches liquid biopsy test for progesterone receptor detection

* Biocept expands commercial offering of clinically actionable biomarker assays with launch of liquid biopsy test for progesterone receptor detection

Jul 14 2017

BRIEF-Biocept, MediNcrease Health Plans announce provider agreement

* Biocept and medincrease health plans announce provider agreement expanding access to liquid biopsy testing Source text for Eikon: Further company coverage:

Jun 21 2017

BRIEF-Biocept awarded U.S. Patent with broad claims for antibody capture of targets of interest on any solid surface

* Biocept awarded U.S. Patent with broad claims for antibody capture of targets of interest on any solid surface including CTCS and other materials shed by solid tumors into blood Source text for Eikon: Further company coverage:

May 22 2017

BRIEF-Biocept reports Q1 loss per share $0.21

* Biocept inc- cash and cash equivalents were $14.0 million as of March 31, 2017, compared with $4.6 million as of December 31, 2016 Source text for Eikon: Further company coverage:

May 11 2017

Earnings vs. Estimates